New answer by Medical Oncologist at Donald and Barbara Zucker School of Medicine at Hofstra/Northwell (October 8, 2025)
In patients with resected stage IB non-small cell lung cancer (NSCLC) harboring EGFR mutations, adjuvant osimertinib may be considered for care. There is some evolving data th...